… efficacy in front-line setting for non-small cell lung cancer (… The aim of our study was to
compare progression-free … -line EGFR TKI due to toxicity or adverse effects, but who did not …

… obtained in a retrospective study, involving patients with a … Such a detrimental effect was
also observed in patients with … A phase III study focused on a comparison between erlotinib …

… We retrospectively analyzed the clinical data of 102 patients … adverse reaction rate compared
with Gefitinib treatment. … improve the clinical efficacy of non-small cell lung cancer. However…

… adverse events (AE), occurrence of adverse events of grade 3 or above (≥3AE), and occurrence
of serious adverse events (… , p < 0.05 in all cases compared with Ch alone). The highest-…

… adverse events (AEs). … compared to erlotinib for advanced NSCLC, which did not respond
to standard first-line chemotherapy (40). A retrospective study revealed that erlotinib/gefitinib …

… risk of grade 3 adverse events, compared to the other EGFR-… better efficacy than and
reduced the risk of CNS progression … A retrospective analysis of osimertinib combined with …

… approved doses of 40 mg (reduction to 30 or 20 mg due to adverse events was permitted). …
retrospective analysis from the Czech Republic comparing the efficacy of afatinib and gefitinib …

… study aimed to summarize the currently available evidence and compare the efficacy and
safety of gefitinib … about the resistance to gefitinib and the adverse effects of platinum-based …

… of adverse events of grade 3 or higher was 14.0 %. … , in this study, there was no difference in
nivolumab effectiveness by … We conducted a multicenter retrospective study on effectiveness …

… , efficacy, and adverse events were retrospectively … Similar to our study, in a recent
retrospective study involving … comparison was impossible due to differences in population, but our …